• Optimi Health is involved in the production of medical-grade psychedelic products.
• Optimi has about 30% insider ownership and is led by chairman John James Wilson, the son of Lululemon founder Chip Wilson.
• The company said the move to invest in a psychedelic company was the result of the Trump administration's recent regulatory revisions.

Shares of SRx Health Solutions, Inc. (SRXH) gained significant investor buzz on Thursday after the company said it is investing in Optimi Health Corp. (OPTH), a pharmaceutical manufacturer that went public on Wednesday.

At the time of writing, SRXH stock was up nearly 5%. Details regarding the value of the investment were not publicly disclosed.

How Did Optimi Health Come Into The Picture?

Optimi Health is involved in the production of medical-grade psychedelic products. SRx Health, which is merging with EMJ Crypto Technologies, said EMJ’s proprietary operating system used quantitative models and artificial intelligence to pick Optimi as an investment opportunity.

The company said the move to invest in a psychedelic company was a result of the recent revision of regulations by the Trump administration to speed up the development of psychedelic drugs to better treat mental health. SRx Health also cited high insider ownership in Optimi, at about 30%, and its strong leadership, led by chairman John James Wilson, the son of Lululemon founder Chip Wilson.

“Our proprietary AI technology investment platform can guide and identify investment themes,” said Michael Young, SRx board member. “This gives us a unique opportunity to invest in companies with positive macro and industry trends.”

What Does Retail Think About SRXH

On Stocktwits, retail sentiment about SRXH turned ‘neutral’ from ‘bullish’ amid ‘normal’ message volumes over the last 24 hours.

Many users on the platform said they bought a significant amount of shares ahead of the SRXH-EMJ merger close and are still buying.

SRXH stock is down 47% so far this year and more than 80% over the past 12 months, underperforming the S&P 500.

For updates and corrections, email newsroom[at]stocktwits[dot]com.